Next Article in Journal
Laser Acupuncture Research: China, Austria, and Other Countries—Update 2018
Previous Article in Journal
The Expanding Role of Radiosurgery for Brain Metastases
Previous Article in Special Issue
The Role of Cannabis within an Emerging Perspective on Schizophrenia
Article Menu

Export Article

Open AccessReview
Medicines 2018, 5(3), 91; https://doi.org/10.3390/medicines5030091

Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis

Department of Pharmacy, University of Pisa, Pisa 56126, Italy
*
Authors to whom correspondence should be addressed.
Received: 27 June 2018 / Revised: 7 August 2018 / Accepted: 9 August 2018 / Published: 15 August 2018
(This article belongs to the Special Issue Cannabinoids for Medical Use)
Full-Text   |   PDF [9417 KB, uploaded 16 August 2018]

Abstract

Recent findings highlight the emerging role of the endocannabinoid system in the control of symptoms and disease progression in multiple sclerosis (MS). MS is a chronic, immune-mediated, demyelinating disorder of the central nervous system with no cure so far. It is widely reported in the literature that cannabinoids might be used to control MS symptoms and that they also might exert neuroprotective effects and slow down disease progression. This review aims to give an overview of the principal cannabinoids (synthetic and endogenous) used for the symptomatic amelioration of MS and their beneficial outcomes, providing new potentially possible perspectives for the treatment of this disease. View Full-Text
Keywords: multiple sclerosis; endocannabinoid system; cannabinoid receptors; monoacylglycerol lipase (MAGL) inhibitors; fatty acid amide hydrolase (FAAH) inhibitors; arachidonoylethanolamine (AEA) reuptake inhibitors multiple sclerosis; endocannabinoid system; cannabinoid receptors; monoacylglycerol lipase (MAGL) inhibitors; fatty acid amide hydrolase (FAAH) inhibitors; arachidonoylethanolamine (AEA) reuptake inhibitors
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Gado, F.; Digiacomo, M.; Macchia, M.; Bertini, S.; Manera, C. Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis. Medicines 2018, 5, 91.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top